Published on 10 Apr 2024 on Simply Wall St. via Yahoo Finance
An Intrinsic Calculation For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Suggests It's 47%...
Key Insights
Regeneron Pharmaceuticals' estimated fair value is US$1,774 based on 2 Stage Free Cash Flow to EquityRegeneron Pharmaceuticals is estimated to be 47% undervalued based on current share price of US$944 The US$1,026 analyst price target for REGN is 42% less than our estimate of fair value
Today we will run through one way of estimating the intrinsic value of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by projecting its future cash flows and then discounting them to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.